Cyclin-dependent kinase 4/6 inhibitor in combination with endocrine therapy versus endocrine therapy only for advanced breast cancer: a systematic review and meta-analysis
| Autor: | Heng Zhang, Li-Li Xie, Deng-Hui Wei, Zhi-Hong Xu, Chun-Sen Xu |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty biology endocrine therapy Cyclin-dependent kinase 4 Kinase business.industry Hazard ratio Cancer medicine.disease meta-analysis Clinical trial Breast cancer cyclin-dependent kinase Hormone receptor Meta-analysis Internal medicine biology.protein medicine Original Article Radiology Nuclear Medicine and imaging business Adverse effect |
| Zdroj: | Translational Cancer Research |
| ISSN: | 2219-6803 2218-676X |
| DOI: | 10.21037/tcr.2019.11.46 |
| Popis: | Background The resistance to endocrine therapy poses a significant challenge to the management of advanced breast cancer with hormone receptor (HR) positive and human epidermal growth factor receptor 2 (Her-2) negative. The purpose of this study was to further examine the efficacy and safety of cyclin-dependent kinase 4/6 inhibitors (CDK4/6Is) in combination with endocrine therapy as a recovery treatment for advanced breast cancer patients. Methods The risk of bias for each included study was assessed using the Cochrane Risk of Bias Tool. The Cochrane Q value, combined with the I2 statistics, were selected to be tested for heterogeneity across the studies. The generic inverse variance was used to pool the hazard ratio and 95% CI of progression-free survival (PFS) and overall survival (OS), while pooled RRs and 95% CI were conducted using the Mantel-Haenszel to appraise the overall response rate (ORR), clinical benefit rate (CBR), and any adverse effects. Results Eight random clinical trials were finally identified. The analysis showed that the duration of PFS was significantly longer in the CDK4/6Is group than in the control group (hazard ratio, 0.55; 95% CI, 0.51–0.60; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|